eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 7/31/2026

1. AMZN
2. RBLX
3. AAPL
4. RDDT
5. COIN

6. NBIX
7. DXCM
8. GH
9. GDDY
10. WU

Get Alerts EFTR Hot Sheet

Price: $0.18 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the JMP Securities Life Sciences Conference taking place May 15-16, 2023 in New York, NY.

Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, will provide an overview of the Company’s clinical development pipeline and corporate strategy. The presentation will be given on Monday, May 15th at 9:30 AM ET.

A live webcast of the event will be available on the "Events and Presentations" page of the Investors section of the Company’s website with a replay available for 90 days following the event. For more information, please visit investors.effector.com.

About eFFECTOR Therapeutics

eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

Contacts:

Investors:		Media:
Christopher M. Calabrese Managing Director LifeSci Advisors917-680-5608[email protected]	Kevin GardnerManaging DirectorLifeSci Advisors617-283-2856[email protected]	Mike TattoryAccount SupervisorLifeSci Communications609-802-6265[email protected]